Skip to main content

Table 3 Association Results of rs28929474 in SERPINA1 with Lung Function, COPD, and COPD Severity

From: Genome-wide association study of lung function and clinical implication in heavy smokers

Phenotype CC (n = 1559) CT (n = 78) TT (n = 8) TT vs. CT vs. CC CT vs. CC TT vs. CT TT vs. CC
β or OR P value β or OR P value β or OR P value β or OR P value
Age at enrollment, years 65.4 ± 8.2 64.5 ± 8.1 53.7 ± 3.9 −2.38 0.0029 −0.92 0.33 −10.8 3.6 × 10−4 −11.7 5.7 × 10−5
Sex (Female vs. Male), n 696 vs. 863 33 vs. 45 2 vs. 6 0.83 0.35 0.91 0.69 0.46 0.35 0.41 0.28
Pack-years of cigarette smoking 52.3 ± 26.6 48.9 ± 26.4 35.2 ± 13.4 −3.97 0.12 −3.10 0.3 −6.62 0.52 −12.3 0.19
Post-bronchodilator FEV1/FVC 0.61 ± 0.16 0.54 ± 0.18 0.39 ± 0.09 −0.087 1.2 × 10−8 − 0.077 2.3 × 10− 5 −0.090 0.21 −0.23 3.2 × 10− 5
Pre-bronchodilator FEV1/FVC 0.59 ± 0.15 0.52 ± 0.17 0.37 ± 0.09 −0.081 9.9 × 10− 8 −0.069 1.7 × 10− 4 − 0.086 0.22 −0.22 3.5 × 10− 5
Post-bronchodilator % predicted FEV1 72.5 ± 25.6 61.3 ± 26.4 33.5 ± 7.89 −13.6 3.5 × 10− 8 − 11.4 9.1 × 10− 5 −22.5 0.037 −38.1 2.2 × 10− 5
Post-bronchodilator FEV1, ml 2115 ± 888 1841 ± 860 1210 ± 240 − 439 2.1 × 10−9 − 329 1.4 × 10− 4 − 1066 1.5 × 10− 4 − 1395 1.4 × 10−7
Pre-bronchodilator % predicted FEV1 65.6 ± 26.1 54.8 ± 26.9 30.2 ± 7.57 −12.9 8.3 × 10− 7 −10.9 5.0 × 10− 4 −17.5 0.12 −34.7 1.6 × 10− 4
Pre-bronchodilator FEV1, ml 1916 ± 883 1629 ± 833 1091 ± 240 − 426 1.1 × 10− 8 − 339 1.2 × 10− 4 − 924 8.1 × 10− 4 − 1263 2.9 × 10− 6
% change in FEV1 (BDR) 13.6 ± 13.5 17.1 ± 18.1 11.6 ± 9.75 2.08 0.13 3.49 0.030 −3.56 0.65 −2.77 0.57
Post-bronchodilator % predicted FVC 90.7 ± 17.7 86.9 ± 17.2 71.5 ± 21.1 −5.23 0.0024 −3.83 0.060 −18.0 0.019 −17.0 0.0070
Post-bronchodilator FVC, ml 3518 ± 1011 3482 ± 1036 3365 ± 1015 − 236 4.6 × 10− 4 − 162 0.042 − 661 0.023 − 822 7.1 × 10− 4
Pre-bronchodilator % predicted FVC 84.4 ± 19.4 78.9 ± 18.6 68.7 ± 21.7 −6.07 0.0018 −5.55 0.017 −12.6 0.13 −14.2 0.038
Pre-bronchodilator FVC, ml 3274 ± 1032 3145 ± 1015 3240 ± 1071 −277 2.0 × 10− 4 − 249 0.0046 − 434 0.16 − 683 0.011
COPD (GOLD stage 2–4 vs. 0), n 803 vs. 539 53 vs. 20 8 vs. 0 2.31 7.8 × 10−4 1.91 0.019 NA NA NA NA
COPD severity (GOLD stage 3–4 vs. 1), n 331 vs. 217 32 vs. 5 8 vs. 0 4.08 0.0036 3.79 0.0081 NA NA NA NA
  1. Association analyses of age or sex were performed using linear or logistic regression without adjustment. Association analyses of Pre-/Post-bronchodilator FEV1 and FVC in ml were performed using linear regression adjusted for sex, age, age2, height, height2, weight, current smoking status, pack-years of cigarette smoking, and the first two principal components. Association analyses of Pre-/Post-bronchodilator FEV1, FVC, and FEV1/FVC, and % change in FEV1 were performed using linear regression adjusted for age, sex, current smoking status, pack-years of cigarette smoking, and the first two principal components. Association analyses of COPD and COPD severity were performed using logistic regression adjusted for age, sex, current smoking status, pack-years of cigarette smoking, and the first two principal components